The Role of Metformin in Non-Melanoma Skin Cancer Risk: Evidence from a Matched Study

The Role of Metformin in Non-Melanoma Skin Cancer Risk: Evidence from a Matched Study

This study analyzed the potential protective effects of metformin, a common diabetes medication, on non-melanoma skin cancers (NMSC) — basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — using a large and diverse U.S. health database called All of Us. Skin cancer poses significant risks, particularly in patients with darker skin tones, due to delayed diagnosis and unique risk factors. For example, SCC in African American patients has a much higher metastasis risk (20-40%) compared to sun-induced SCCs in Caucasian populations (1-4%).

Atorvastatin and Chemotherapy Combination Therapy: A Preclinical Study

Atorvastatin and Chemotherapy Combination Therapy: A Preclinical Study

An innovative study reveals the powerful synergistic effects of combining Atorvastatin (a cholesterol-lowering drug) with standard chemotherapy medications, demonstrating enhanced anti-cancer properties against both blood cancer and lung cancer cells. Laboratory tests showed significant cell death rates of up to 99% when combining these medications in specific ratios, particularly when Atorvastatin was paired with Cytarabine or Doxorubicin.